Q-Square Business Intelligence
Q-Square Business Intelligence is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects with BRAF-V600 Mutant Solid Tumors.
Sponsor C4 Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The Phase 2 dose-expansion phase was not initiated.
- A 12 April 2023 protocol amendment revised prior-anticancer-therapy eligibility from requiring BRAFi-naive participants to requiring prior BRAFi treatment when appropriate.
- A 6 February 2024 protocol amendment added CFT1946 plus cetuximab arms for BRAF V600-mutant colorectal cancer and updated enrollment stopping rules and eligibility criteria.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)
Sponsor Celcuity Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients
Sponsor Sangamo Therapeutics France
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Recruitment was permanently stopped before full enrolment was achieved, resulting in a smaller-than-planned sample size.
- Early recruitment termination meant that the planned Bayesian Optimal Interval dose-escalation process did not meet its pre-specified stopping criteria.
- Limited available biopsy material constrained interpretation of chronic graft-related findings.
- Mixed lymphocyte reaction assay data were limited by low peripheral blood mononuclear cell availability after anti-thymocyte globulin lymphodepletion, precluding conclusions.
These findings describe the trial, not the service provider’s performance or responsibility.
A Multicenter, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
Sponsor Vera Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study of Emavusertib in Combination with an Approved Bruton Tyrosine Kinase Inhibitor in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies
Sponsor Curis Inc.
- Start (EU)
- Latest update
- Estimated end
Long-Term Follow-Up of Patients Who Have Received An Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR-Treg therapy, TX200-TR101) In A Prior Clinical study
Sponsor Sangamo Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Sponsor Apollomics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Q-Square Business Intelligence?
The 2026-10-09 snapshot links Q-Square Business Intelligence to 7 distinct CTIS trials. Recorded services include Statistical analysis, Data management, Electronic data capture. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Q-Square Business Intelligence?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Dermatology, Endocrinology, Gastroenterology. Recorded phases include Phase 1, Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Q-Square Business Intelligence conducted?
The linked trials record locations in 13 countries, including Spain, Belgium, Italy, Germany, France. These are trial locations, not confirmed office locations or countries where Q-Square Business Intelligence delivered services.
What can this page tell me about Q-Square Business Intelligence's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 3 recorded name variants under Q-Square Business Intelligence. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Q Square Business Intelligence Corp.
- Q-Square Business Intelligence Corp.
- Q-Square Business Intelligence, Corp.